Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay.

Jamie Feng¹, Sameena Khan¹, Thomas K Waddell², Kazuhiro Yasufuku², Zachary Coyne¹, Deirdre Kelly¹, Nicholas Meti¹, Najib Safieddine³, Michael Ko⁴, Andrew Pierre², Shaf Keshavjee², Elliot Wakeam², Laura Donahoe², Marcelo Cypel², Jonathan Yeung², Marc de Perrot², Negar Ahmadi³, Sayf Gazala³, Carmine Simone³, David Parente⁴, Mary R Rabey¹, Jennifer H Law¹, Janice J N Li¹, Alexandra Salvarrey², Lisa W Le⁵, Andrew Seto⁶, Michael Cabanero⁶, Ming-Sound Tsao⁶, Christodoulos Pipinikas⁷, Amber Chevalier⁷, Scott V Bratman⁸, Natasha B Leighl⁹

¹Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

²Division of Thoracic Surgery, University Health Network (UHN), Toronto, Ontario, Canada.

³Division of Thoracic Surgery, Michael Garron Hospital, Toronto, Ontario, Canada.

⁴Division of Thoracic Surgery, Unity Health Toronto, Toronto, Ontario, Canada.

⁵Department of Biostatistics, University Health Network, Toronto, Ontario, Canada.

⁶Division of Pathology and Cytogenetics, Laboratory Medicine Program, UHN, Toronto, Ontario, Canada.

⁷NeoGenomics Inc., Fort Myers, Florida.

⁸Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

⁹Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: natasha.leighl@uhn.ca.

PubMed DOI

Abstract

INTRODUCTION: Circulating tumor DNA (ctDNA) has emerged as an important prognostic factor in patients with cancer. Management of early stage NSCLC remains challenging with a high rate of disease recurrence. METHODS: In this prospective cohort, 153 patients with clinical stage I NSCLC (75.8% pathologic stage I) underwent real-time plasma ctDNA testing using a tumor-informed whole exome sequencing…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.